Multiple sclerosis (MS) causes a wide range of symptoms involving the brain, optic nerves, and spinal cord. Research is only just beginning to reveal who is at risk and what causes the condition.
MS is a chronic condition affecting 2.8 million people worldwide. While treatment options are currently limited, trials of several new approaches are underway.
Researchers believe that MS is an autoimmune disorder. This type of illness involves the immune system attacking healthy cells, much as it would attack viruses or bacteria.
In the case of MS, the immune system attacks the myelin sheath that surrounds nerve cells. The attack causes lesions to form, and over time, these cause scarring, which leads to nerve damage and reduced function.
As a result of this damage, a person with MS may experience numbness and tingling sensations, fatigue, muscle weakness, dizziness and vertigo, memory issues, and vision problems, among other symptoms.
There are four types of MS: clinically isolated syndrome (CIS), relapsing-remitting MS, primary progressive MS, and secondary progressive MS.
CIS is a single episode of MS-like symptoms that lasts for at least 24 hours. People with CIS do not necessarily have MS, but experiencing an episode can be the first sign of the condition.
Treating MS involves interdisciplinary care, including rehabilitation, disease-modifying drugs (DMARDs), and complementary and alternative therapies.
Scientists do not fully understand the risk factors for MS and the mechanisms of the condition. However, they are making new headway in the search for answers and improvements in treatment.
What does the latest research show about the risk factors, mechanisms, and treatments of MS? In this Special Feature, Medical News Today takes a closer look.
French neurologist Jean-Martin Charcot first described the features of MS in 1868. He noted the differences between this condition and the tremor of paralysis agitans, a symptom of the neurological condition later named Parkinsons disease.
The three symptoms associated with MS at the time were called Charcots triad. They included a characteristic tremor, involuntary eye movements, also known as nystagmus, and scanning speech, which some call staccato or explosive speech.
Decades later, the invention of MRI scans helped doctors diagnose MS. Treatment with steroids became commonplace, and doctors then began to use medications in a class of drugs called interferons. The Food and Drug Administration (FDA) first approved interferons for use in people with MS in 1993.
Although scientists and healthcare professionals understand the defining features of MS, several aspects of the condition remain a mystery.
While researchers recognize that MS is an autoimmune condition, they do not understand why immune cells attack myelin.
Also, diagnosing MS is still an ambiguous process because its symptoms are similar to those of many other health conditions.
In addition, experts do not know why women are 23 times more likely to be diagnosed with MS than men.
Research suggests that risk factors of MS include a lack of vitamin D or sunlight, smoking, obesity, a history of infection with the Epstein-Barr virus, being female, and possibly having inherited specific genes, as well as environmental factors.
More recently, the gut microbiota has emerged as a possible risk modulator.
A recent overview of clinical research found that people with MS had larger populations of Pedobacteria, Flavobacterium, Pseudomonas, Mycoplana, Acinetobacter, Eggerthella, Dorea, Blautia, Streptococcus, and Akkermansia bacteria in their intestines than people without MS.
People with MS also had reduced populations of Prevotella, Bacteroides, Parabacteroides, Haemophilus, Sutterella, Adlercreutzia, Coprobacillus, Lactobacillus, Clostridium, Anaerostipes, and Faecalibacterium bacteria.
Researchers speculate that balancing out the populations of gut bacteria in people with MS may reduce inflammation and the overactivation of the immune system.
Research from the MS Society Edinburgh Centre for MS Research found that people with MS had reduced numbers of inhibitory neurons, compared with people who did not have the condition.
However, people with MS had as many stimulating neurons as those without the condition. This was true even for people who had received their MS diagnoses many years earlier.
These findings help reveal the types of neurons affected by MS, shedding more light on how the condition evolves within the body. The research may also offer insight into treatments that could protect the targeted neurons.
DMARDs that health authorities have recently approved as MS treatments include cladribine (Mavenclad) and siponimod (Mayzent) for relapsing-remitting and active secondary progressive forms of the condition.
Cladribine targets lymphocytes, white blood cells responsible for attacks on myelin. Siponimod harnesses specific white blood cells that attack myelin and prevents them from circulating in the body.
However, due to their interactions with the immune system, these drugs may lead to a reduction in lymphocytes, making a person vulnerable to infections.
The medicines actions may also contribute to reduced responses to vaccines in people who receive routine vaccinations. With the introduction of COVID-19 vaccines, scientists have investigated whether people with MS who take medications such as cladribine can have adequate responses to vaccines.
The latest research indicates that people taking cladribine do produce protective antibodies to other common vaccines, despite having decreased lymphocyte levels induced by the medication.
This result gives scientists and others in the medical community hope that people who take these drugs for MS will have similarly adequate responses to COVID-19 vaccines.
Some scientists are currently investigating the potential for stem cell therapy for MS. In a phase 1 study conducted at the Karolinska Institute, in Stockholm, Sweden, seven people with progressive MS received infusions of stem cells derived from each participants own bone marrow.
As early as 7 days after administration of the stem cell therapy, researchers found evidence of positive changes in the participants immune systems. At 12 weeks, five out of six participants had no new characteristic lesions on follow-up MRI brain scans.
As their understanding of the condition evolves, many scientists are investigating the root cause of MS.
An analysis of the current data has revealed a possible connection between gut health and the condition. Data revealing relationships between the gut microbiota and the brain continually emerge, and scientists are hopeful that diet modifications, probiotics, and certain drugs that balance the gut microbiome will play a role in MS treatment.
Also in development are remyelination and neuroprotection therapies. The latter aim to protect the axons and myelin from further damage, while the former could restore lost function for people with MS.
Meanwhile, immunotherapy drugs would protect the nerves from destruction and rebuild neurons that have already sustained damage.
Another potential treatment in phase 1 trials is a tumor necrosis factor-alpha (TNF-alpha) inhibitor called MYMD-1. TNF-alpha is a type of cytokine produced by white blood cells that regulates some aspects of the immune system.
Overproduction of this cytokine is associated with several autoimmune conditions, including MS. MYMD-1 is a new type of TNF-alpha blocker that shows promise as a treatment for MS and other conditions.
Trials for therapies involving the gut microbiome, stem cells, neuroprotective treatments, remyelination, and MYMD-1 are still in the earliest stages. However, the possibilities provide hope that ongoing research will lead to effective ways to prevent MS and better methods of treatment.
- Stem Cells Market to Witness Robust Expansion Throughout the Forecast Period 2018-2026 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - April 20th, 2021
- Animal Stem Cell Therapy Market Study Report and In-deep Analysis 2020 2026 The Courier - The Courier - April 20th, 2021
- Global Cord Blood Stem Cells Market to 2026 Industry Perspective, Comprehensive Analysis, and Forecast KSU | The Sentinel Newspaper - KSU | The... - April 20th, 2021
- Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell... - April 18th, 2021
- StemSynergy Therapeutics' Notch1-Selective Small Molecule Inhibitor Prevents Tumor Growth by Ablation of Cancer Stem Cells - Business Wire - April 16th, 2021
- US researchers create the first human-monkey chimaera, in the midst of a raging debate on such experimentation - The Financial Express - April 16th, 2021
- CAR T-Cell Therapy Enters the Arena in Multiple Myeloma With Ongoing Research Ahead - OncLive - April 16th, 2021
- Treating chronic myeloid leukemia (CML): By phase and more - Medical News Today - April 16th, 2021
- Cellino Biotech developing tech to help scale stem cell therapies - MedCity News - April 14th, 2021
- Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021: Methods of Commercializing iPSCs are Diverse and Continue to Expand -... - April 14th, 2021
- A Massive New Gene Editing Project Is Out to Crush Alzheimer's - Singularity Hub - April 14th, 2021
- eQcell Inc Announces the Appointment of Members of the Board of Directors - BioSpace - April 14th, 2021
- Researchers Receive Grant to Improve Cellular Therapies to Treat 'Incurable' Diseases - University of Arkansas Newswire - April 14th, 2021
- Lonza Celebrates 20th Anniversary of Nucleofector Cell Transfection Platform - Technology Networks - April 14th, 2021
- New consortium aims to accelerate development of stem cell-based therapies for Huntingtons disease - News-Medical.Net - April 10th, 2021
- Strengthening the Stem Cell Industry Through Better Regulation - The Regulatory Review - April 10th, 2021
- Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021: Research, Patents, Funding Events, Industry Partnerships, Biomedical... - April 10th, 2021
- Stem Cell Transplantation May Be Offered Less Often as a Treatment Option for Some Patients with Mantle Cell Lymphoma - Curetoday.com - April 10th, 2021
- Real-time imaging shines light on the coordination of neural stem cell activation - News-Medical.net - April 10th, 2021
- Searching for Molecular Targets in Myeloid Malignancies and Beyond - OncLive - April 10th, 2021
- Fitore Nutrition Launches Spectrum + to Better the Lives of Children With Autism - Influencive - April 10th, 2021
- Cancer Stem Cells Market By Size Estimation, Growth Rate, Regional Analysis With with the CAGR of 11.0% Over the Forecast Period. KSU | The Sentinel... - April 10th, 2021
- global market for regenerative medicines is predicted to grow at a CAGR of 13.99% over the forecast period of 2020-2030 - GlobeNewswire - April 10th, 2021
- Adipose Derived Stem Cell Therapy Market New Business Opportunities And Investment Research Report 2020-2027 | Coherent Market Insights KSU | The... - April 10th, 2021
- Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021 - GlobeNewswire - April 10th, 2021
- New local publication and book-signing event - Bowling Green Daily News - April 6th, 2021
- Human blastocyst-like structures generated entirely from pluripotent stem cells. Shifting the paradigm of developmental biology? - ESHRE - April 3rd, 2021
- Comprehensive Report on Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Cellular Dynamics... - April 3rd, 2021
- New approach to CAR T gene therapy yields efficient and longer-lasting response against HIV - News-Medical.Net - April 3rd, 2021
- New research offers hope to women with POI - Austin Daily Herald - Austin Herald - April 3rd, 2021
- Stem Cell Therapy Market to Witness Strong Growth Over 2021-2027 | Key Manufacturers Overview- Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals,... - April 3rd, 2021
- The entelechy test: embryos and simbryos - BioNews - March 30th, 2021
- Global Regenerative Medicine Conference, NCRM NICHE with Fujio Cup Quiz (FCQ), E-poster and Edogawa NICH - Times of India - March 30th, 2021
- Study: Anti-Inflammatory Therapies Could Reduce Heart Disease Risk in Elderly Patients With Clonal Hematopoiesis - Pharmacy Times - March 30th, 2021
- Can This New Electrophysiology Technology Boost Neurology Research? - Labiotech.eu - March 30th, 2021
- Stem Cell Characterization and Analysis ToolMarket Size, Share, Industry Analysis, Forecast and Global Research Report to 2027 - The Market Eagle - March 30th, 2021
- Researchers describe the systems that manage embryonic stem cells - Microbioz India - March 26th, 2021
- Cell therapy player Fate Therapeutics sees CSO and 12-year veteran Shoemaker retire - FierceBiotech - March 26th, 2021
- Stem cells - a mix of promise and hype - ABC News - March 26th, 2021
- Global Vaccine, Insulin and Stem Cell Market Research Report Covers, Future Trends, Past, Present Data and Deep Analysis 2020-2026 The Bisouv Network... - March 26th, 2021
- Stem cell therapy could help restore debilitating age-related muscle loss - News-Medical.Net - March 24th, 2021
- Cell Culture: Disrupting the Meat Industry - Open Access Government - March 24th, 2021
- Canine Stem Cell Therapy Market Research and New Developments 2021-2026 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - March 24th, 2021
- Two In-Space Production Applications and Calls for Proposals Announced - Genetic Engineering & Biotechnology News - March 24th, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Market 2020-2027 Onset of Advanced Technologies to Upsurge the Growth The Courier - The Courier - March 24th, 2021
- Trending News: Stem Cell Cartilage Regeneration Market New Research Report 2021 to 2027| Anika Therapeutics, Zimmer Biomet, BioTissue Technologies -... - March 24th, 2021
- Researchers Have Grown 'Human Embryos' From Skin Cells. Is It Ethical? - The Wire Science - March 20th, 2021
- Stem cell therapy could help bear recover from painful disease - FOX 35 Orlando - March 20th, 2021
- The J&J vaccine was developed with stem cells. Thats caused confusion and division among Catholics. - OregonLive - March 20th, 2021
- Adipose-derived Stem Cell Overview Market Trend, Growth, Size, Forecast, Key Players and Competitive Landscape Research Report by2027 The Courier -... - March 20th, 2021
- Scientists Grow Tear Gland Organoids That Can Actually Cry - Freethink - March 20th, 2021
- Rheumatoid Arthritis Stem Cell Therapy Market Predicted to Witness Surge in the Near Future 2018 to 2028 KSU | The Sentinel Newspaper - KSU | The... - March 18th, 2021
- Catholic opinions on Johnson & Johnson vaccine highlight debate between hardliners on abortion and others in the church - Fairfield Citizen - March 18th, 2021
- Original Error: Retracing the History of the Mutation That Gave Rise to Cancer Decades Later - SciTechDaily - March 11th, 2021
- Super-resolution system microscopy can reveal pluripotency and differentiation of live stem cells - News-Medical.net - March 11th, 2021
- New multi-faculty Centre for Cell Therapy Translation gives UCalgary skin in the game for regenerative medicine research - UCalgary News - March 11th, 2021
- Policymakers urged to extend the 14-day limit on embryo research - BioNews - March 11th, 2021
- The Sacramento Business Journal announced that Cate Dyer, CEO, and founder of StemExpress, has been selected as one of SBJ's 2021 Most Admired CEOs -... - March 11th, 2021
- Coronavirus Insights: Ongoing Updates Covering The Impact On Induced Pluripotent Stem Cell Market - The Courier - March 11th, 2021
- Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations - GlobeNewswire - March 11th, 2021
- Adipose Stem Cells (ASCS) Market 2021 Global Analysis and Outlook: LifeCell, EMD Millipore, Geron, BrainStorm Cell Therapeutics, Minerva... - March 11th, 2021
- Stem cells: Therapy, controversy, and research - March 5th, 2021
- Human embryo research beyond the primitive streak - Science - March 5th, 2021
- Research Antibodies Market Size to Reach USD 5325.8 Million by 2027 | Increasing R&D Activities in the Fields of Oncology, Neurobiology, and Stem... - March 5th, 2021
- Stem Cell Therapy Market Research Reveals Enhanced Growth During The Forecast Period 2017 2025 FLA News - FLA News - March 5th, 2021
- Astrocytes Derived from Patients with Bipolar Disorder Malfunction - UC San Diego Health - March 5th, 2021
- Global Stem Cell Therapy Market Booming Market To Hit $ 18.66 Billion By 2027 With Top Key Players Osiris Therapeutics, Inc. (US), MEDIPOST Co., Ltd.... - March 5th, 2021
- Stem Cell Derived Exosome Production in Stirred-Tank Bioreactors - BioProcess Insider - March 5th, 2021
- Researchers study iPSCs to uncover genetic causes of disease - Drug Target Review - March 5th, 2021
- Moderna Hires Harvard Stem Cell Researcher Jonathan Hoggatt as Director of Hematology: What You Need to Know - Benzinga - March 5th, 2021
- Intrapericardial injection provides a less invasive means of treating cardiac injury - News-Medical.Net - March 5th, 2021
- Individualized brain cell grafts reverse Parkinson's symptoms in monkeys - University of Wisconsin-Madison - March 3rd, 2021
- New Controversy for Stem Cell Therapy That Repairs Spinal Cords - The Great Courses Daily News - March 3rd, 2021
- Cell Therapy Company Raises $160 Million to Advance iPSC-Derived Therapies to Clinic - BioSpace - March 3rd, 2021
- NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis T - PharmiWeb.com - March 3rd, 2021
- A region within GLI1 gene could potentially be targeted as cancer treatment - News-Medical.Net - March 3rd, 2021
- Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights - Galveston County Daily News - March 3rd, 2021
- Global Animal Stem Cell Therapy Market 2020 2025 Research Report Segment Outlook, Growth Potentials and Analysis of COVID-19 Worldwide Outbreak KSU... - March 3rd, 2021
- Global Autologous stem cell and Non-stem cell based Therapies Market- Industry Analysis, Growth, Segmentation and Forecast-2019-2027 - The Bisouv... - March 3rd, 2021
- Stem Cell manufacturing Market Witness an Outstanding Growth and Strong Revenue and Forecast 2027 KSU | The Sentinel Newspaper - KSU | The Sentinel... - March 3rd, 2021